newsfilter
← Latest News
GlobeNewswire·

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMDPositive recommendation is based on data from the LADDER, Archway and Portal studies